0.00
—
Close of 2 Nov 2026, in USD
About Affymax
Its shares trade under the ticker AFFY. It has been listed since 15 December 2006. In the fiscal year to 31 December 2013, it reported revenue of $1.4m and a net loss of $14.4m. At that date it held total assets of $7.4m and shareholders' equity of −$1.4m.
Affymax, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York. The company went IPO on 2006-12-15. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The firm has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 15 Dec 2006
- Employees
- 4
- Website
- affymax.com ↗
Leadership
Pay as last reported
- Mr. John OrwinIndependent Chairman of the Board, since 2010$1.9m
- Mr. Jonathan CouchmanPresident, Chief Executive Officer, Director, since 2014
- Mr. Mark ThompsonChief Financial Officer$97,488
- Ms. Grace ShinGeneral Counsel
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Drug Technology: Affymax Inc possesses a unique and innovative drug technology that sets it apart from its competitors.
- Strong Intellectual Property: The company holds several patents and intellectual property rights, providing a competitive advantage and protecting its innovations in the market.
- Strategic Partnerships: Affymax Inc has established partnerships with key stakeholders, such as pharmaceutical companies and research institutions, allowing for collaboration and resource sharing.
Weaknesses
- Limited Product Portfolio: The company currently has a limited product portfolio, which may hinder its ability to generate diversified revenue streams and compete in multiple therapeutic areas.
- Lack of Financial Stability: Affymax Inc faces financial challenges due to limited funding and insufficient capital reserves, potentially constraining its growth opportunities and research capabilities.
- Dependency on Partnerships: The company heavily relies on strategic partnerships for research, development, and commercialization activities, making it vulnerable to the performance and decisions of its partners.
Opportunities
- Growing Global Pharmaceutical Market: The global pharmaceutical market is expected to experience significant growth, presenting opportunities for Affymax Inc to expand its product offerings and reach a wider customer base.
- Emerging Markets: Expansion into emerging markets with unmet medical needs can provide Affymax Inc with untapped market potential and new revenue streams.
- Technological Advancements: Rapid advancements in technology, such as precision medicine and personalized therapies, offer opportunities for Affymax Inc to leverage its innovative drug technology and cater to specific patient populations.
Threats
- Intense Competition: The pharmaceutical industry is highly competitive, with numerous established and emerging players. Affymax Inc may face challenges in differentiating its products and services from competitors.
- Stringent Regulatory Environment: Strict regulatory requirements and lengthy approval processes can hinder the timely commercialization of Affymax Inc's products, leading to potential delays and increased costs.
- Market Volatility: The pharmaceutical market is subject to fluctuations, such as changes in healthcare policies, reimbursement rates, and market trends, which can impact Affymax Inc's financial performance and market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.